Podcasts about Grade

Ben Criddle talks BYU sports every weekday from 2 to 6 pm.Today's Host: Ben Criddle (@criddlebenjamin) and Co-Host: (ronthe3manweav)Subscribe to the Cougar Sports with Ben Criddle podcast:Apple Podcasts: https://itunes.apple.com/us/podcast/cougar-sports-with-ben-criddle/id99676

New customers get 50% Off with code [INSERT CODE] at GLD.com------JUDGE TYCO SPECIAL: NOW STREAMING ON CRAVETHE OFFICE MOVERS - SEASON 1: ON NETFLIX CANADAThis week we reflect on the villain roles played so well you dislike the actor in real life... then:⭐️ When your parents want the house in complete darkness⭐️ Not having a laptop as a man⭐️ Jury Duty on Amazon⭐️ My Last Physical Media: Flavor of Love in Grade 7⭐️ Scary Movie 6⭐️ Actual Scary Movies⭐️ When your computer doesn't turn on⭐️ When your phone dies and you log out of life⭐️ TV Prices are reasonable⭐️ Blu-Ray prices are not⭐️ The Meat-to-Nose swipe of the century⭐️ When you finally earn enough credit card points⭐️ When you drop the weight on your self doing the bench-pressWATCH THE VIDEO EPISODE--------Tweet us and follow us InstagramLike the show? SUBSCRIBE to and RATE Random Order on:» Apple Podcasts: https://podcasts.apple.com/us/podcast/random-order-podcast» Spotify: https://open.spotify.com/show/1mO9AL0wCGeF6hFEa7MhoV Advertise on Random Order via Gumball.fmSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Der Titel der heutigen Episode ist: »Künstliche Vernunft?«, und ich freue mich besonders, dass sich Jan Juhani Steinmann wieder zu einem Gespräch bereit erklärt hat. Wir spannen in dieser Episode einen weiten Bogen von der Frage, was Intelligenz, Bewusstsein und Selbstbewusstsein sind, welche Rolle Biologie, Leib und Körper sowie Theologie spielen können, um dann auf die Frage der künstlichen Intelligenz und Vernunft zu kommen. Was hat es mit der sogenannten Singularität und dem Transhumanismus auf sich, und warum könnte die Bevölkerungsentwicklung des Menschen eine wesentliche Rolle spielen? Am Ende legt Jan seine Vorstellung eines positiven Bildes des Zusammenspiels von Mensch und Technik dar. Dr. Juhani Steinmann ist in Bern geboren, mütterlicherseits Finne, ist Philosoph, Dichter und Theologe. Er hat Philosophie, Allgemeine und Vergleichende Literaturwissenschaften, Politikwissenschaften sowie Theologie in Zürich, Berlin, St. Andrews, Heidelberg, Rom und Cambridge studiert. Forschungsaufenthalte wurden in Kopenhagen, Helsinki und Oxford durchgeführt. Unter der Betreuung von Prof. Konrad Paul Liessmann hat er 2021 an der Universität Wien in Philosophie promoviert. Zurzeit forscht er am Institut Catholique de Paris, an der Università di Roma LUMSA sowie an der Faculty of Divinity der University of Cambridge zur poetischen Phänomenologie im Kontext des Denkens von Kierkegaard, Nietzsche und Heidegger. Er ist ferner Begründer des Kollektivs Omnibus Omnia. Nebst wissenschaftlichen Publikationen in Philosophie und Theologie publiziert er auch Dichtung. Besonders möchte ich auch seine Bücher erwähnen, vorzugsweise: »Kritik der künstlichen Vernunft. Vorspiel eines Anathemas« und »Das Vorfaltenlicht. Die Alpen und das Valley«. Diese beiden Werke gehören zusammen, sind wie Geschwister zu betrachten. Das erste ist eine Techniktheologie/-philosophie, das zweite eine Technik- und Naturpoesie, da die Gedichte dazu im Silicon Valley und in den Alpen geschrieben wurden. Vorzugsweise deshalb, weil sie zum Thema des heutigen Gesprächs passen. Wir beginnen das Gespräch mit der Frage nach dem Begriff der Intelligenz. Wie kann man sich diesem Begriff nähern, der ja schon beim Menschen mit vielfältiger Bedeutung überladen ist — und dann wird er auch noch für künstliche Intelligenz verwendet? »Intelligenz ist eine Form der Vermittlung innerhalb von Relationen — also, es werden Dinge in ein Verhältnis zueinander gestellt.« Wie leitet sich daraus (beim Menschen) Selbstbewusstsein und Bewusstsein allgemein ab? »Der Mensch ist ja sicherlich das erste Wesen, das überhaupt eine Definition dieser Eigenschaften, die es an sich selbst bemerkt, geleistet hat. […] Intelligenz erkennt sich selbst durch den Menschen als jenem Wesen, das intelligent ist, oder zu sein scheint.« Was folgt daraus in theologisch/philosophischer Reflexion? Was bedeutet der Begriff Logos und wie steht er in Zusammenhang mit Intelligenz und Bewusstsein? Gibt es einen metaphysisch ur-ontologischen Garanten von Bedeutung? Ist Gott der Garant für die Vernünftigkeit der Vernunft? Oder sind diese Eigenschaften des Menschen schlicht emergente Phänomene, die aus der biologischen Komplexität seiner selbst entspringen? Ist die »künstliche Intelligenz« äquivalent zur menschlichen/biologischen Vernunft? Oder ist dies grundsätzlich zu anthropomorph gedacht? Wie ist der Zusammenhang zwischen diesen philosophisch/theologischen und operationalen Ansätzen der Intelligenz — etwa ausgedrückt durch Intelligenztests und dergleichen? Was bedeutet der Begriff des Geistes? Was sind die verschiedenen Modi der Rationalität, in denen Menschen operieren? Was ist dianoetisches und noetisches Denken? Gibt es eine göttliche — hypernoetische Dimension? Welche Rolle spielen Instinkt und Intuition? Wie nehmen wir Stimmungen wahr? Was hat es mit der Leiblichkeit auf sich? Zu welcher Leistung sind nun Algorithmen und Maschinen fähig? »Maschinen imitieren im Grunde Dianoia — zugleich aber simulieren sie noetische Vernunft« Was ist Behaviorismus, und wie hilft er, die aktuellen Entwicklungen zu verstehen? Ist der Mensch frei? Was bedeutet der Begriff der Freiheit überhaupt, besonders wenn man sich auf die sogenannte Willensfreiheit bezieht? Ziehen wir die Grenze zwischen Maschine und Mensch vielleicht nur darum, weil wir gekränkt sind, weil Maschinen nun etwas können, was wir für rein menschlich gehalten haben? Ist das vielleicht nur eine weitere Ergänzung zu den drei Kränkungen des Menschen nach Sigmund Freud? »Warum sollten wir uns selbst abschaffen, hinfällig machen?« Aber haben wir ab einem bestimmten Zeitpunkt überhaupt noch die Wahl? Was ist die Rolle des Leibes für Vernunft und Intelligenz und vor allem für die noetische Dimension? Was ist Informationismus? Sind Maschinen gar die nächste evolutionäre Stufe auf unserem Planeten? Kehren wir zur Frage der Freiheit und Willensfreiheit zurück. Ist das vielleicht eine Frage, die viel weniger philosophische Tiefe hat, als häufig dargestellt wird? Um Wittgenstein zu bemühen: »Die meisten Sätze und Fragen, welche über philosophische Dinge geschrieben worden sind, sind nicht falsch, sondern unsinnig.« Wie zeigt sich das, was wir Autonomie nennen, wie kann es sein, dass wir uns selbst als frei empfinden? »Das ist ja ein schönes Paradox der Freiheit, dass man sich freiwilliger Notwendigkeit hingibt. […] Freiheit ist eine Stimmung — man fühlt sich frei. […] Du willst ja nur, was du willst.« Was folgt daraus? »Wir sind schon immer gefangen in den Bedingungen unseres Hier-Seins. Und von innen — aus diesem System heraus — kann die Freiheit nicht bewiesen werden. So zumindest erscheint es uns.« Schopenhauer sagt: »Ich kann zwar tun, was ich will, aber nicht wollen, was ich will.« Ist dies eine Widerlegung der Freiheit — wie Schopenhauer es annimmt — oder kann man andere Schlüsse ziehen? Gibt es einen Grund anzunehmen, dass es Intelligenz nur beim Menschen, respektive in biologischen Systemen, gibt? Beziehungsweise, dass es überhaupt andere intelligente Wesen außerhalb von mir selbst gibt (die solipsistische Idee)? Was passiert aber mit verkörperter künstlicher Intelligenz, etwa in der Robotik? Sind Roboter nur Körper und kein Leib? Ist es ein Kategorienfehler, die biologische mit der kulturellen und technischen Evolution zu vergleichen? »Die Kultur hat den Menschen schon von der Evolution entfremdet.« Kommt die biologische Evolution zu einem Ende, und wird sie von neuen Gesetzmäßigkeiten abgelöst? Was ist das Zusammenspiel von Technik, Maschinen und Macht? Ist Technik co-evolutionär mit dem Menschen? Gibt es einen Sprung von der Humanität zur Transhumanität? Was versteht man unter (technologischem) Transhumanismus, und was sind die Ursprünge? Allgemeiner gefragt: Ist der Mensch eine Aporie, die man überwinden muss? Wie sieht es mit biologisch/technischen Mischformen, kybernetischen Organismen aus? Steuern wir auf eine Singularität zu, die in etwa so gelesen werden könnte: »Es gibt keinen Gott — programmieren wir doch die Superintelligenz als neuen Gott« So beantwortet Ray Kurzweil die Frage: Is there a god: »Not yet«. »Wir haben keinen Begriff, was auf uns zukommt. Das könnte die Abschaffung des Menschen bedeuten — oder vielleicht eine relativ gemäßigte Koexistenz. Aber wir dürfen es nicht unterschätzen.« Wie groß ist diese Gefahr? Ist es überhaupt eine Gefahr? Können wir diese Technologien kontrollieren und regulieren? »Ich sehe keinen Grund anzunehmen, warum wir obsolet sein möchten.« Wie wahrscheinlich ist das Entstehen einer Superintelligenz, die möglicherweise sogar global wirksam wird? Was wäre die Voraussetzung dafür? Aber selbst, wenn es zu keiner Singularität oder Superintelligenz kommt, ist die Menschlichkeit nicht schon durch die Integration in permanent verfügbare dianoetische Systeme gefährdet? Werden wir unsere Urteilskraft an die Maschine delegieren? Mit welchen Folgen? Außerdem dürfen fundamentale Prinzipien komplexer Systeme nicht vergessen werden: Führen mehr Daten etwa zu mehr Sicherheit oder zu mehr Unsicherheit? Und wie können wir das entscheiden? Woher kommt das Neue in die Welt? »Die Welt ist nicht nur ihre Messbarkeit. Sie ist nicht die Summe ihrer Daten. […] Die Welt ist immer mehr und anders, als sich in einem Ordnungssystem sagen lässt.« Zum Ende des Gesprächs folgt eine vielleicht unerwartete Abzweigung: Bevölkerungen kollabieren weltweit. Im Gegensatz zu den langjährigen Warnungen tritt also das Gegenteil einer Bevölkerungsexplosion mittel- und langfristig ein. Dies gilt praktisch weltweit und besonders in den Industrienationen. Eine dramatisch alternde und gleichzeitig schrumpfende Bevölkerung wird aber erhebliche Probleme haben, ihre ökonomische und militärische und damit geopolitische Position aufrechtzuerhalten. Wird daraus ein enormer Druck entstehen, Robotik und künstliche Intelligenz als Ersatz für fehlende Arbeitskraft zu entwickeln und einzusetzen? Übernehmen — mit Marx gesprochen — die Maschinen also irgendwann die proletarische Arbeit? Gibt es doch noch ein alternatives und hoffnungsfroheres Paradigma? Also zu den Paradigmen der: Humanität Transhumanität Theo-Humanität Was ist darunter zu verstehen? »Lasst uns doch gemeinsam uns vergöttlichen — ob es Gott gibt, oder nicht. Das macht uns zu würdevollen und schönen Wesen.« Wollen wir Technologien, die den Menschen als Idioten betrachten, oder die uns als Menschen erhöhen? Referenzen Andere Episoden Episode 147: Digitale Kolonie oder Souveränität? Ein Gespräch mit Wilfried Jäger und Kevin Mallinger Episode 143: Auf Sand gebaut? Episode 139: Komfortable Disruption Episode 137: Alles Leben ist Problemlösen Episode 134: Das Werdende, das ewig wirkt und lebt? Transzendent oder Transient Episode 132: Fragen an die künstliche Intelligenz — eine konstruktive Irritation Episode 129: Rules, A Conversation with Prof. Lorraine Daston Episode 125: Ist Fortschritt möglich? Ideen als Widergänger über Generationen Episode 123: Die Natur kennt feine Grade, Ein Gespräch mit Prof. Frank Zachos Episode 121: Künstliche Unintelligenz Episode 119: Spy vs Spy: Über künstlicher Intelligenz und anderen Agenten Episode 104: Aus Quantität wird Qualität Episode 98: Ist Gott tot? Ein philosophisches Gespräch mit Jan Juhani Steinmann Episode 85: Naturalismus — was weiß Wissenschaft? Episode 68: Modelle und Realität, ein Gespräch mit Dr. Andreas Windisch Fachliche Referenzen  Webseite und Lebenslauf von Jan Juhani Steinmann YouTube Kanal von Jan Juhani Steinmann Jan Juhani Steinmann, Kritik der künstlichen Vernunft, Lepanto (2025) Jan Juhani Steinmann, Das Vorfaltenlicht. Die Alpen und das Valley, Wieser Verlag (2025) Immanuel Kant, Kritik der reinen Vernunft (1781) Peter Sloterdijk, Kritik der zynischen Vernunft, Suhrkamp (1983) Ludwig Wittgenstein, Tractatus logico-philosophicus (1922) Kränkungen der Menschheit, Sigmund Freud und folgende Andy Clark, Being There, MIT Press (1998) Steve Taylor, How a Flawed Experiment “Proved” That Free Will Doesn't Exist, Scientific American (2019)

See omnystudio.com/listener for privacy information.

Kelly and Sharon kick things off with their 90's Playlist Pick of the Week, before Kelly shares the behind-the-scenes story of how she was able to play Janet Jackson's “All For You” on the Montreal radio station where she works! They celebrate Catherine O'Hara receiving a well-deserved honour at the Actor Awards, including a heartfelt tribute from Seth Rogen. The ladies also bring you details on the upcoming Yellowstone spinoff The Madison, starring Michelle Pfeiffer and Kurt Russell and what fans can expect from the expanding universe. Horror fans won't want to miss their take on Scream 7 and why it was absolutely essential for Neve Campbell to return to the franchise. Kelly and Sharon discuss Neve's importance to the series, how she handled her previous salary dispute with strength and professionalism and why she remains the emotional anchor of Scream. Sharon also reflects on the passing of James Van Der Beek and how his death has inspired many to live fully in the present and embrace life's opportunities. Plus, the Question of the Week: What 90's movie franchise deserves more installments? The episode wraps with Kelly's Trivia and Sharon's 1998 Rewind - and yes, there are some hilarious Grade 7 and 8 photo confessions along the way. Thanks for listening to 90's NOW!  

With the Cheltenham Festival just around the corner, we take a different approach to the formbook by diving into RaceiQ data with Racing TV analyst Page Fuller. RaceiQ uses GPS tracking technology to measure performance metrics such as jumping efficiency, stride length, entry speed into obstacles, and finishing sectionals, offering a completely different perspective on how horses perform in top-level races. Page joins Emmet Kennedy to analyse the key metrics behind the leading contenders for the biggest races at Cheltenham, highlighting the performances that stand out in the data and identifying the horses whose numbers suggest they could have a major impact at the Festival. Page has produced Racing TV's Cheltenham Festival RaceiQ data pack covering all 13 Grade 1 races. The aim isn't tipping winners, but identifying the performances and metrics that stand out in the data and understanding what they may tell us about how these races could unfold.

Doug Foltz explains how he used AI to solve a real coach-development bottleneck: mentor coaching doesn't scale. By building a competency rubric and an AI "agent" that evaluates coaching transcripts, Doug's team reduced hours of expert analysis to minutes—then re-centered the human work where it matters most: reflection, agency, and a short mentor-coaching conversation. The bigger idea: "communal co-intelligence"—AI not just as a personal assistant, but as a tool that helps a whole coaching community preserve culture, build consistency, and scale development without losing what makes coaching human. Episode description How do you scale mentor coaching when you don't have the budget—or the hours? Doug Foltz (Content Engineering & Value Alignment Lead at Gloo, DMin candidate at Asbury, and longtime church-planting coach) shares how he built an AI-supported mentor-coaching loop: a detailed competency rubric + an AI evaluator that reviews transcripts in minutes. But Doug also warns about a hidden danger: AI can bypass reflection, which is essential for adult learning. So they intentionally added "friction" back into the process—reflection first, then AI feedback, then a short human coaching conversation. Along the way, Doug introduces a powerful concept: communal co-intelligence—AI that strengthens a community's shared language, values, and coaching culture. Key moments (timestamps) 0:02–1:20 – Who Doug is + why Brian calls him the "AI guy" 1:49–3:21 – The real problem: coaching training doesn't stick without mentor coaching 3:34–5:06 – Doug's solution: a rubric + AI agent that evaluates transcripts (levels 1–3) 6:44–8:15 – The twist: reflection is essential; AI can accidentally remove it 8:28–9:00 – The human loop: 15–20 minute mentor conversation after reflection + report 10:38–14:35 – Why AI matters: replaces 3–4 hours of expert analysis with minutes 15:04–16:15 – The church's role: protect what's uniquely human; set boundaries 16:27–19:16 – "Communal co-intelligence": AI + a coaching community's culture and standards 21:24–23:00 – What they observed: fast growth from Level 1 → Level 2; harder jump to Level 3 23:29–25:46 – Craft guild model: learn the fundamentals, then innovate without losing the core 28:57–31:14 – What's next: agentic systems, tools + data access, and AI as "work orchestrator" Key ideas AI can scale mentor coaching by doing the transcript evaluation quickly and consistently. Reflection is non-negotiable in adult learning; AI can "steal" it by doing the thinking for you. The solution is intentional friction: reflection → AI feedback → short human mentor coaching. Agency matters: don't make AI the all-knowing guru; keep the learner's authority intact. Communal co-intelligence: AI can reinforce a shared coaching culture across many coaches. Early gains can be rapid (novice → intermediate), but advanced mastery takes longer. The future is agentic systems that combine tools + data + context to orchestrate real work. Quotable lines (pull quotes) "We really can't scale coaching very well." "Mentor coaching is what makes the training stick." "My process actually bypasses [reflection] entirely." "We added a friction point… and we made them reflect." "You don't want the AI to be the all-knowing guru." "That's the part of the process that we said, we're going to replace." (re: 3–4 hours of evaluation) "Communal co-intelligence… it's the AI with our coaching community." "It becomes this orchestrator of work within an organization." Discussion questions (for Learning Lab / staff meeting) Where would AI help us scale without compromising what we value most? What part of our development process must remain human-only? Where might AI accidentally remove reflection, struggle, or ownership? What would a "reflection-first" workflow look like for our coaches or trainers? What are the risks of communal AI (shared culture) becoming static or overly controlling? If AI becomes an "orchestrator of work," what data is off-limits—and why? Practical takeaway AI is best used as a leverage tool—not a replacement for learning. Let it do the heavy lift of analysis and pattern recognition, then spend your human time where it counts: reflection, discernment, presence, and coaching conversations that build ownership and growth. If you design it well, AI doesn't dilute your culture—it can actually help you scale it.

Life without Evander begins with a 1-0 loss on the road to Minnesota. Adam and Adam break it down and dish out some harsh criticism of our second striker position.Listen up and see if you agree with our assessment and the MOTM pick!@TheKingAdRock73 @NinoOne @sbucks67 @crackityFC @ComeOnYouFCC @fccincinnati @Zuhause513 @MLS #AllForCincy #FCCincy #YAL #WestEndBoys

The Orlando Magic finally pick up a win and Paolo bounces back after some brutal loses. Sometimes you have to face the facts and the truth hurts the Magic are just an average team in the NBA. Athletes make a lot of money but how much is Cameron Brink spending on a chef? Find out on Mic'd Up! Prime Time spits out the hot takes and Kravitz grades them with Grade the Take! Golf betting analyst Len Hochberg, NBA analyst from Rotowire.com Nick Whalen, and college basketball analyst from the Locked on College Basketball podcast joins Game On!

Thief of Everything Part 3 (Isaiah 6:1-5)Speaker: Mark CoxWed, Mar 4, 2026Houston's First Baptist Church - Sienna Campus (Missouri City, TX).FUSE: 6th-12th Grade

Paul Ferguson, author of the Weatherbys Cheltenham Festival Betting Guide, joins Emmet Kennedy alongside Total Performance Data's Adam Mills for a Cheltenham Festival Handicaps Special presented by 1xBet Ireland. This episode focuses on eight of the most competitive and potentially rewarding races of the week, highlighting the key horses to include in your shortlists, along with several big-priced selections that could make a difference during the Festival. Paul and Adam also put forward their leading bets, including an 8/1 NAP and a 6/1 NAP, as they break down where they see the strongest opportunities across the handicap programme.

Steiny & Guru discuss the job Mike Dunleavy has done since taking over and if he's the guy to lead this team's future.

Welcome to Tablesetters, where early-season baseball storylines are evaluated through context, projection, and structural impact rather than isolated spring highlights. As camps begin to stabilize, several early narratives are beginning to shape the broader landscape of the 2026 season — from international competition to emerging prospects and roster uncertainty around the league. We begin with the return of the World Baseball Classic, which arrives just as MLB spring training reaches its most competitive stretch. The tournament brings together 20 national teams competing across Tokyo, San Juan, Houston, and Miami, running through March 17. Japan enters as the defending champion after defeating Team USA in the 2023 final, while the United States returns with a roster built to pursue redemption. The Dominican Republic, Venezuela, and Puerto Rico also enter the tournament with lineups capable of making deep runs. Exhibition games leading into the tournament have already produced early signals. Team USA delivered one of the loudest statements, routing the San Francisco Giants 15–1. Paul Skenes dominated in his outing, striking out four hitters across three innings without issuing a walk, immediately reminding everyone why he has quickly become one of the most overpowering pitchers in the sport. Offensively, Alex Bregman launched a home run while Roman Anthony — a late addition to the roster after Corbin Carroll suffered a broken hand — delivered a two-run homer. The lineup surrounding them featured star power throughout with Aaron Judge, Bryce Harper, Bobby Witt Jr., and Byron Buxton. Japan's preparation was less smooth. Samurai Japan dropped an exhibition game despite a solo homer from Masataka Yoshida, a reminder that even the defending champions are still working through early-March rhythm. The tournament officially begins when Chinese Taipei faces Australia in Tokyo, opening the round-robin stage where five-team pools compete for two quarterfinal spots. Team USA opens its tournament Friday against Brazil before quickly facing Great Britain, Mexico, and Italy as Pool B begins to take shape. From international baseball we move to a structural shift arriving in Major League Baseball this season: the Automated Ball-Strike challenge system. Rather than replacing home plate umpires entirely, the league is introducing a hybrid model. Each team begins a game with two challenges, and only the pitcher, catcher, or hitter can initiate a challenge immediately after a call. If the challenge is successful, the team keeps it. Spring training has quickly become the testing ground for how teams will actually use the system. The Minnesota Twins have been among the most aggressive teams in challenging calls, leading the league in overturned decisions early in camp as they experiment with the margins of the strike zone. Meanwhile, the Athletics have stood out for efficiency, posting the highest challenge success rate in baseball so far by winning roughly seventy percent of their appeals. Leaguewide data suggests about half of all challenges are overturned, reinforcing the idea that the biggest edge may belong to players with elite strike-zone awareness rather than teams that simply challenge the most. Spring training has also produced several intriguing individual and organizational storylines. In Detroit's system, Kevin McGonigle is beginning to look like one of the most advanced young hitters in professional baseball. The 21-year-old shortstop recently opened an exhibition game by launching the first pitch he saw from former All-Star Luis Severino for a home run. McGonigle's combination of strike-zone discipline, elite contact ability, and emerging power recently earned him an 80-grade hit tool evaluation, the highest grade scouts can assign to a hitter. In limited spring action he has posted a .400/.471/.667 line, further reinforcing the belief that he could eventually become one of the defining hitters of the Tigers' next competitive window. In Colorado, the organization's long search for stability at first base continues more than a decade after Todd Helton's retirement. This spring that conversation centers around Charlie Condon and TJ Rumfield. Condon, the third overall pick in the 2024 draft out of Georgia, arrived in professional baseball with one of the most dominant offensive seasons in recent NCAA history, hitting 37 home runs while batting .433. His raw power could eventually play extremely well at Coors Field. Rumfield represents a different profile — a more experienced hitter who spent all of last season in Triple-A hitting .285 with an .825 OPS. Colorado now faces a familiar decision between accelerating a high-upside prospect or relying on the steadier upper-minors bat. Atlanta is dealing with a far more complicated roster situation. Jurickson Profar is facing a potential 162-game suspension after testing positive for a performance-enhancing drug for the second time within the past year. Under MLB's Joint Drug Prevention and Treatment Program, a second violation results in a full-season suspension and forfeiture of salary. Profar is expected to appeal the decision through the MLB Players Association, which leaves the Braves in a difficult holding pattern as they attempt to plan their Opening Day roster. If the suspension stands, Atlanta will suddenly need to replace a projected middle-of-the-lineup bat. Finally, one of the most closely watched prospects in baseball continues to generate attention in Pittsburgh. Konnor Griffin, the 19-year-old shortstop and the No. 1 prospect in the sport, has already launched three home runs in limited Grapefruit League action. Griffin's power-speed combination has drawn comparisons to some of the most dynamic young players in the game. Last season he hit .333 with 21 home runs and 65 stolen bases across three minor league levels, eventually finishing the year at Double-A. The bigger question now is timing. If Griffin were to make the Opening Day roster, he would become the first teenage hitter to debut in the majors since Ken Griffey Jr. in 1989. The Pirates may still choose to delay that debut for development or service-time reasons, but early spring performances are beginning to make that decision far more complicated. Spring training often produces noise, but the themes beginning to emerge this year feel more substantial: the return of baseball's biggest international tournament, a technological change that could reshape the strike zone conversation, and a wave of young talent preparing to define the next era of the sport. The season is approaching quickly. And the real signals are starting to appear.

Benjamin Meyer, Building Enclosure Business Director with Siplast, and Andrea Wagner Watts, Building Science Education Manager for GAF | Siplast Building & Roofing Science, join us to talk about their webinar, "Strategies for High-Performance Below-Grade Waterproofing". Register for this free webinar

This show is brought to you by AFS Automated Financial Services, your business's payment solution. Hosts invite listeners to "Give Donald Trump a grade," discuss recent U.S. strikes on Iran, Trump's record on the economy and immigration, tariffs, and national security, and field strong caller reactions and jokes. The episode also covers local events like the Spirit of America Bike and Car Show, upcoming guests and community news, and encourages listeners to call or text with their opinions.

In honor of International Women's Day on March 8, this episode of Grade 1 View highlights the power, resilience, and impact of women shaping the future of nurse anesthesia. Dr. Bimpe ‘Bebe' Adenusi shares her remarkable journey from clinical chemist to CRNA, educator, program director, national leader, and founder of the Nigerian American Nurse Anesthetist Association. With authenticity and humility, she reflects on the mentors who shaped her path, the challenges of stepping into leadership, and the responsibility of lifting the next generation. Here's some of what we discuss in this episode:

In this episode, Kenny goes through several categories to give MLB The Show 25 a final grade. Subscribe on YouTube at youtube.com/@kdjtv611.

TF S03 | E18| In this episode of Thinking Faith, Deacon Eric Gurash and Dr. Brett Salkeld respond to a thoughtful question from Grade 9–10 students at Miller High School: How can I know when God is talking to me? Drawing on the spiritual wisdom of St. Ignatius of Loyola, the conversation explores Christian discernment through self-awareness, honesty, and paying attention to the movements of the heart over time. They explain the difference between spiritual consolation and desolation, clarifying that these are not simply good or bad feelings, but experiences related to freedom, clarity, hope, and closeness to God. The episode offers practical guidance on creating space to hear God's voice through silence, prayer, spiritual reading, Mass, confession, adoration, and the daily Examen, while cautioning against making major decisions during times of desolation. Listeners are encouraged to trust that God's voice often sounds like truth spoken within, to remain grounded in Church teaching, and to grow patiently in freedom and faith as God continues to shape their spiritual lives. 00:19 Podcast Welcome 03:22 Question God Speaking 03:46 Ignatius Discernment Basics 05:05 Silence and Self Awareness 05:58 Ignatius Story and Boredom 08:21 Consolation vs Dopamine Crash 10:40 Examen and Honest Reflection 12:02 True Voice vs False Voice 15:59 Church and Moral Guardrails 18:31 Crime and Punishment Example 20:52 Everyday Choices and Consolation 21:45 Fruits Of The Spirit 22:32 Consolation Versus Desolation 23:53 Do Not Decide Desolate 24:35 Dad Story And Space 27:58 Lies Reduce Your Options 29:03 Temporary States And Clarity 31:44 Many Good Choices 33:42 Discernment In Sacraments 36:13 Garden Conditions For Growth 38:05 God Changes Our Minds 38:44 Closing Thanks And Blessing

He's the Vice Chair at America First Policy Institute's Center for American Security, and he's got all the receipts on Trump's use of force in Iran.

In “Too Many A's,” Sharona and Boz revisit a popular media narrative about “grade inflation,” starting with a Harvard-focused story that treats “too many A's” as a crisis—while quietly mixing two incompatible purposes of grading: ranking/sorting and communicating learning. They argue that if grades are meant to report mastery, “more A's” isn't a scandal—it's the goal (with the important caveat that the bar still matters). From there, they dissect a recent viral article claiming “easy A's” harm students' long-term outcomes, and they do what they teach: go to the original research, separate correlation from causation, and interrogate definitions—especially a math-heavy “lenient grader” metric that depends on standardized tests and other inputs that may be misaligned, inequitable, or just plain bad proxies. Along the way, they call out how quickly commentary slides into storytelling (“the mechanism is not difficult to imagine”) and how often alternative grading gets blamed without evidence—ending with a clear takeaway: we can't evaluate “too many A's” until we're honest about what grades are for, what evidence they should represent, and what data we're willing to treat as trustworthy.LinksPlease note - any books linked here are likely Amazon Associates links. Clicking on them and purchasing through them helps support the show. Thanks for your support!One Solution for Too Many A's? Harvard Considers Giving A+ Grades. (NY Times Gift Link)Easy A's, Less Pay: The Long-Term Effects of Grade Inflation, Denning Et Al (Not Yet Peer Reviewed)Easy A's, lower pay: Grade inflation's hidden damage, New Article referencing the above articleThe True Cost of Grade Inflation at Harvard, article in Harvard MagazineEpisode 88 – Unearned Grades: Remaking the Conversation about Grade “Inflation”, The Grading PodcastResourcesThe Center for Grading Reform - seeking to advance education in the United States by supporting effective grading reform at all levels through conferences, educational workshops, professional development, research and scholarship, influencing public policy, and community building.The Grading Conference - an annual, online conference exploring Alternative Grading in Higher Education & K-12.Some great resources to educate yourself about Alternative Grading:The Grading for Growth BlogThe Grading ConferenceThe Intentional Academia BlogRecommended Books on Alternative Grading:Grading for Growth, by Robert Talbert and David ClarkSpecifications Grading, by Linda NilsenUndoing the Grade, by Jesse StommelFollow us on Bluesky, Facebook and Instagram - @thegradingpod. To leave us a comment, please go to our website: www.thegradingpod.com and leave a comment on this episode's page.If you would like to be considered to be a guest on this show, please reach out using the Contact Us form on our website, www.thegradingpod.com.All content of this podcast and website are solely the opinions of the hosts and guests and do not necessarily represent the views of California State University Los Angeles or the Los Angeles Unified School District.MusicCountry Rock performed by Lite Saturation, licensed under a Attribution-NonCommercial-NoDerivatives 4.0 International License.

This is NOT OK: If a child is not reading on grade level by 3rd grade, they are 4x LESS LIKELY to graduate high school, and if living in poverty, 13x LESS LIKELY!Carol Goglia, CEO of Catch Up & Read is focused on one of America's most urgent challenges: early literacy. She has spent her career turning strategy into impact, from her early days at Frito-Lay to leading one of the country's most powerful giving movements at Communities Foundation/North Texas Giving Day.In this episode, Carol shares this idea of joy as a catalyst for learning and retention. From the “joyful results clubs” that make kids ask, “Is it Catch Up & Read day?” to lessons corporate leaders can borrow from the nonprofit world, this conversation is a powerful reminder that sometimes the biggest business signals start in the smallest moments.If you care about the future talent pipeline, team development, or the long game of leadership, I think this will resonate!

In this episode, we sit down with Head of School Dr. Ryan Kimmet to tackle a growing crisis in modern education: the disappearance of play. While many schools view play as a luxury for the early years, The Harley School treats it as a critical engine for learning from Nursery through Grade 12. Dr. Kimmet dives into the science and strategy behind "protecting the sandbox." We discuss: Why Harley maintains Middle School recess when most schools phase it out. How "playful" physics labs lead to deeper conceptual understanding than traditional lectures. How a culture of play builds the "competitive edge" Harley graduates need for the future of work. The psychological link between unstructured time and navigating the "growing pains" of adolescence. Join us for a deep dive into why "seat time" isn't the same as "learning time," and how protecting the art of play creates students who aren't just high achievers, but creative thinkers ready to iterate and innovate.

One of the best jockeys of his generation and a multiple Grade 1 winner, Aidan Coleman joins Emmet Kennedy and Adam Mills to preview the key novice races at the 2026 Cheltenham Festival. The focus begins with a highly competitive running of the Arkle Novice Chase, where Lulamba, Kopek Des Bordes, Romeo Coolio, Kargese, Irish Panther and Steel Ally are set to clash. Aidan reveals the horse he would most like to ride and gives his insight into how the race may unfold. Attention then turns to the Brown Advisory Novices' Chase, with a strong field including Final Demand, Kaid d'Authie, The Big Westerner, Wendigo, Western Fold, Kitzbuhel, Oscars Brother and Sixmilebridge. The team assess the leading contenders and put forward a 16/1 betting angle in the 3m1f contest. The discussion then shifts to the novice hurdlers, with leading contenders Old Park Star, Mighty Park, El Cairos, Mydaddypaddy, Idaho Sun and Sober Glory analysed in detail, before a deep dive into the Turners Novice Hurdle featuring No Drama This End, Skylight Hustle, Talk The Talk, Act Of Innocence and others.

What if the real reason you're not showing up online isn't strategy… but fear of judgment?In this episode, I'm joined by mindset coach and business strategist Ivana Ivanek to unpack the real reason so many brilliant, mission-driven women hold back from visibility.We talk about the fear of societal rejection, outgrowing old circles, and why you're overthinking your third-grade cousin's opinion instead of focusing on the people who actually need your work.If you've ever felt cringe hitting “post,” worried about who's watching your stories, or watered yourself down online… this conversation will shift something in you.This is about personal branding, yes.But more than that? It's about identity, courage, and stepping into the leader your business needs you to be.If you LOVED this episode, make sure you share this on your Instagram stories and tag us @contentqueenmariah and @ivanaivanek_.⁠⁠⁠LEARN THE DETAILS OF A CONTENT STRATEGY WITH MY FREE AUDIO GUIDE⁠⁠⁠KEY EPISODE TAKEAWAYS

Essential viewing! The 2026 Cheltenham Festival is almost upon us, so tune in as Sporting Life ambassador Willie Mullins guides us through another exceptionally strong Closutton team for the Festival.The most successful trainer in Cheltenham Festival history gives us the latest on his two-time Gold Cup hero Galopin Des Champs, Irish Gold Cup winner Fact To File and five-time Grade 1 winner Gaelic Warrior.The Master of Closutton also provides his thoughts on Majborough ahead of his Champion Chase mission, the latest on Lossiemouth, updates on plenty of exciting novices and much more too!0:00 Introduction0:21 Galopin des Champs3:11 Fact To File5:47 Gaelic Warrior8:17 Majborough10:27 Lossiemouth14:40 Poniros16:07 Final Demand18:49 Kaid D'Authie19:39 Kopek des Bordes22:28 Mighty Park24:38 Bambino Fever27:25 Proactif27:47 Selma De Vary29:11 Ballyburn30:42 Dinoblue31:45 Spindleberry32:12 Jade de Grugy

This week on VG Pulse, we’ve got a whole pile of stupid to go over! We start off with side notes of new phones and giant movie posters, before we dive into the stupid where we discuss Discord being stupid! Oh why do companies have to be stupid… after the stupid, we discuss the rocky future of Microsoft, Toyota making their own weird game engine, and some incredibly upsetting losses in the legacy gaming sphere these past few weeks. After the news we realize we’ve gone very long on this one, and skip right on to finishing off with talk of anime!! All this and more up next on VGP … Continue reading "VG Pulse 430: NASA Grade Engineering"

Hear how Calendar Mike became a hero at work because he remembered his 3rd Grade safety class, Stop, Drop and Roll. JK gets his ass chapped due to the lack of enthusiasm over the Gold Medal Hockey Game, by the 3BI guys.

Two leaders, two visions, two itineraries. Prime Minister Mark Carney is once again travelling abroad to strengthen Canada's trading relationships with fellow middle powers like India, Japan and Australia. How much sway does Canada hold in this new geopolitical era? Anne-Marie Slaughter, former Obama-era senior U.S. State Department director, joins The House to weigh in on this middle-power moment.And Pierre Poilievre is headed to Europe in his first official overseas trip as Leader of the Opposition, following a speech that laid out the Conservative vision for tackling a protectionist United States. Political insiders Marci Surkes and Kate Harrison take a look at both big trips, and the stakes for both parties.Next: OpenAI was the focus of intense scrutiny this week after it was revealed the ChatGPT developer did not inform police about troubling content from an online account belonging to the Tumbler Ridge shooter. The House checks in with The Logic's Murad Hemmadi about whether big tech companies can be trusted to regulate themselves.Then, as the world's youngest generations are set to bear the brunt of today's decisions, some governments around the world are taking steps to ensure they have a champion — and Canadian advocates want Ottawa to do the same. House producer Benjamin Lopez Steven speaks with Wales' Future Generations Commissioner Derek Walker, as well as Paul Kershaw of Generation Squeeze, Ontario Senator Rosemary Moodie and a classroom of Grade 8 students about whether the Welsh model could work in Canada.And as Russia's war on Ukraine grinds on, and peace talks remain deadlocked, Canada's Ambassador to Ukraine Natalka Cmoc speaks with guest host Tom Parry about a difficult winter in Kyiv and the horrors she's heard on the ground from Ukrainians.This episode features the voices of:Anne-Marie Slaughter, CEO of think tank New America and former senior official at the U.S. State DepartmentMarci Surkes, former senior advisor to Justin Trudeau and chief strategy officer at Compass RoseKate Harrison, Conservative strategist and vice chair at Summa StrategiesMurad Hemmadi, AI reporter for The LogicDerek Walker, Future Generations Commissioner for WalesKatie Richmyre, Grade 8 teacher at St. Mother Teresa High SchoolPaul Kershaw, founder of Generation SqueezeSenator Rosemary MoodieNatalka Cmoc, Canada's ambassador to Ukraine

2.27.26 Hour 3, Kevin Sheehan asks callers for their thoughts on what they think Dan Quinn's A+ grade on the NFLPA team report card means for how much faith the Commanders players have in him. Kevin Sheehan and Producer Max recaps some of the standout NFL Combine showings and recent news in the NFL.

2.27.26, Kevin Sheehan asks callers for their thoughts on what they think Dan Quinn's A+ grade on the NFLPA team report card means for how much faith the Commanders players have in him.

Join NFL Legends James "Deebo" Harrison and Joe Haden as they react to the Pittsburgh Steelers horrible grade in the NFLPA Report Cards, whether the Steelers should target Ty Simpson in the 2026 NFL Draft, Fernando Mendoza choosing not to throw at the NFL Scouting Combine and much more! Download the PrizePicks app today and use code DEEBOJOE to get $50 in lineups after you play your first $5 lineup! https://prizepicks.onelink.me/LME0/DEEBOJOE Timeline:00:00 - Joe's Mexico Experience15:45 - NFLPA Report Cards41:35 - Steelers meet with Ty Simpson (Timestamps may vary based on advertisements.) #Club #NightcapSee omnystudio.com/listener for privacy information.

Mark and Tommy Football talk about the Steelers and their failing grades in the latest report card. Vince Trocheck joins the show to talk about winning olympic gold.

Mark and Tommy Football talk about the Steelers and their failing grades in the latest report card. Vince Trocheck joins the show to talk about winning olympic gold. See omnystudio.com/listener for privacy information.

Willard and Dibs discuss the job that Steve Kerr has done this season.

Breaking down the survey results and what the fan-related critique really means.

Mike Johnson, Ali Mac, and Beau Morgan react to the NFLPA's annual survey and report grades getting leaked last night, react to the Atlanta Falcons' NFLPA report card grades, react to Falcons new Head Coach Kevin Stefanski getting a C minus grade for this past season as the Cleveland Browns' Head Coach, and talk about how Kevin Stefanski's NFLPA report card grade isn't good, but isn't all bad either.

Mike Johnson, Ali Mac, and Beau Morgan continue to react to the NFLPA's annual survey and report grades getting leaked last night, continue to react to the Atlanta Falcons' NFLPA report card grades, continue to react to Falcons new Head Coach Kevin Stefanski getting a C minus grade for this past season as the Cleveland Browns' Head Coach, and explain why they think the Browns quarterback controversy last season may've played a part in Kevin Stefanski's C minus grade.

HR2 - Kevin Stefanski's situation in Cleveland a lot to do with NFLPA report card grade In hour two Mike Johnson, Ali Mac, and Beau Morgan continue to react to the NFLPA's annual survey and report grades getting leaked last night, continue to react to the Atlanta Falcons' NFLPA report card grades, continue to react to Falcons new Head Coach Kevin Stefanski getting a C minus grade for this past season as the Cleveland Browns' Head Coach, explain why they think the Browns quarterback controversy last season may've played a part in Kevin Stefanski's C minus grade, play a round of Fair or Foul for the halftime portion of the show, discuss if they think the Falcons will trade back from the 48th overall pick, talk about the push to bring NHL hockey back to Atlanta happening again after the U.S. Men's and Women's hockey teams brought home gold in this year's Winter Olympics in Milan, and then close out hour two by reacting to the latest news, rumors, and reports in the NFL as they go In The Huddle.

Louie & Barry are back with their weekly SoCal Saturday preview!The Grade 2 Buena Vista is the feature.Check out our friends at AMWAGER! They have a 100% deposit match for new customers up to $150.

Pakistan is trading airstrikes with Afghanistan, and the region is heating up fast. Meanwhile, Iran sits in that dangerous gray zone — not officially at war, but surrounded by military buildup and diplomacy that feels like two people texting “we need to talk.” The most likely outcome with Iran is contained escalation, not full regional war — but miscalculation is undefeated. Pakistan may have conventional advantage at home, yet chaos along that border never stays local. And India? India is watching its rival fight the kid everyone knew in 7th grade — unpredictable, loud, and willing to flip the desk. Opportunity and risk are arriving together.

Ashley Mailloux and Mike Beer preview Sunday's Late Pick 5, headlined by the Grade 2 Rebel Stakes at Oaklawn Park.

David Aragona and Gino Buccola preview Saturday's All-Stakes Pick 5, headlined by the Grade 2 Fountain of Youth at Gulfstream Park.

Mike Schopp reacts to the Bills having their field as their worst grade on the NFLPA report cards

More calls and how did the Lions grade out as an organizationSee omnystudio.com/listener for privacy information.

Weapons Grade on Sub FM 24th February 2026 - https://www.sub.fm

Dr. Bishal Gyawali and Dr. Tessa Cigler share the new, comprehensive, evidence-based update of the ASCO guideline on the use of hematopoietic colony-stimulating factors in patients with cancer. They discuss recommendations on primary prophylaxis, secondary prophylaxis, and treatment of febrile neutropenia along with stem cell mobilization, efficacy, safety, duration, dosing, and administration of CSFs – including biosimilars. They highlight where it is appropriate to use a CSF, and importantly, when not to use a CSF. They touch on the significance of individual patient considerations and cost implications, and future work to refine the risk factors for the development of complications of febrile neutropenia. Read the full guideline, "White Blood Cell Growth Factors: ASCO Guideline Update" at www.asco.org/supportive-care-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/supportive-care-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02938     Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Bishal Gyawali from Queen's University in Kingston, Ontario, Canada, and Dr. Tessa Cigler from Weill Cornell Medicine in New York, New York, co-chairs on "White Blood Cell Growth Factors: ASCO Guideline Update." Thank you for being here today, Dr. Gyawali and Dr. Cigler. Dr. Bishal Gyawali: Thank you very much for having me. It's a pleasure. Dr. Tessa Cigler: Hi there. Nice to be here as well. Brittany Harvey: Great. And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Cigler and Dr. Gyawali, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then I'd like to dive into the guideline that we're here today to talk about. So first, what prompted an update to this guideline on the use of hematopoietic colony-stimulating factors in patients with cancer, and what is the scope of this updated guideline? Dr. Bishal Gyawali: The last version of the guidelines from ASCO on this topic was back in 2015, so it has been more than a decade since ASCO had a guideline on the use of G-CSF in patients with cancer receiving treatment. So it was due for an update because there has been a lot more evidence based on not necessarily new drugs, but evidence for proper timing of these agents and the duration of these agents, as well as there have been a lot of new biosimilars, and there are questions about are these biosimilars equivalent or how do we choose among these different options. One is that content of the evidence that has evolved over time in the last decade, but also I think the last time we had these guidelines, the ASCO guidelines were not incorporated to have those evidence GRADE tables. So the quality of the ASCO guidelines itself has evolved over the years, so we wanted to have a new version of the guideline that includes not only the new evidence, but also contains those evidence GRADE tables that will help to quantify the benefits. And so I think it was high time, and even more than that, the newer ASCO guidelines for any guideline, they also include considerations of cost, access, equity, and all these factors that were not included in the previous version of the guideline. So I think it's only natural that with time the guideline should also evolve. Dr. Tessa Cigler: I agree completely, and just as a framework, as we all know, neutropenia and its complications, including febrile neutropenia and infections, are still an important toxicity of many myelosuppressive chemotherapies. And these neutropenic complications do require prompt evaluation and treatment and often hospitalization, and we know that hematopoietic colony-stimulating factors, which I'm going to refer to as growth factors, can reduce the duration and severity of neutropenia and the risk of febrile neutropenia, so it remains an important topic in the practice of clinical oncology. Brittany Harvey: Absolutely. It's an important topic for both clinicians and for patients who are receiving treatment for their cancer. And as you said, there was a substantial amount of literature to review here and updating everything to be in line with the GRADE evidence rating system, so there was a lot of work that you both put into this. So then next, I'd like to review the key recommendations of this guideline by clinical question. So first, what factors did the expert panel identify that should influence the decision to administer primary prophylaxis of febrile neutropenia with a CSF? Dr. Bishal Gyawali: Yeah, so I think that constitutes one of the most important recommendations in our guidelines about primary prophylaxis with G-CSF. And this is important because not only it's about when to use it, it's also about when not to use it, as in the ASCO "Choosing Wisely" campaign has also made some recommendations about this. So our guideline recommendations are also aligned with that. So first of all, we recommend that primary prophylaxis with G-CSF is recommended when the risk of febrile neutropenia because of the chemotherapy regimen is equal to or more than 20% unless an alternative chemotherapy regimen with comparable efficacy and safety that does not need G-CSF is available. And the quality of evidence to make this recommendation is high, so we give a strong strength of recommendation for this. Having said that, even for patients where the risk of febrile neutropenia is not necessarily 20%, it's a little lower, but because of other patient-related factors, the patient is at a higher risk of complications from febrile neutropenia, such as age, comorbidities, and other factors, in such case primary prophylaxis with G-CSF should be offered. And we also make a recommendation that if G-CSF is not affordable or available, then antibiotic prophylaxis can also be offered, but the evidence quality for this is low, and the strength of recommendation is very conditional. A couple of things to highlight here would be that, I think Dr. Cigler can attest to that, we ran into lots of problems about finding the data for the evidence base to say what are the patient-related factors that actually make them at a higher risk of febrile neutropenia, you know, like how did that 20% benchmark come about? Why 20%? Or when we say even if it's less than 20%, if based on other comorbidities, if the risk is higher, we tried to dig into that evidence. For example, we're talking about our "Box 1" in the guideline, what is the evidence for each item we have included under that "Box 1"? And we tried to do a lot of search to find the evidence for that, and some of them do have strong evidence, and that will tie into our future research ideas as well. And some of them actually don't have such solid evidence too, so that was one of the reasons why we ran into lots of problems about how do we quantify whether someone is at a high risk of febrile neutropenia and where that 20% benchmark comes from. Dr. Tessa Cigler: And definitely, because there's not very clear data, our guidelines definitely leave room for physician discretion in all these situations. Brittany Harvey: Absolutely. I find that in a lot of these guidelines the key point is that there's a lot of shared decision-making with patients after talking through what risk factors they may have and what is best for them in their individual clinical scenario. So then moving on to secondary prophylaxis, what factors did the expert panel identify that should influence the decision to administer secondary prophylaxis of febrile neutropenia with a CSF? Dr. Tessa Cigler: So for patients who've already experienced a neutropenic complication from a previous cycle of chemotherapy, the question is which patients should then receive prophylactic G-CSF for subsequent cycles of chemotherapy. And without a lot of evidence again to guide us, the panel really felt strongly that secondary prophylaxis should be used when a treatment delay or when a reduced dose of chemotherapy would be thought to compromise cure rates or survival outcomes. We do note that in many situations, certainly a dose reduction or a delay would be a very reasonable alternative or an additional strategy to G-CSF administration. Dr. Bishal Gyawali: Yeah, I think it's more like if there is going to be compromise in outcomes without using G-CSF, as in if we can't maintain the dose intensity and that's going to lead to inferior outcomes, then we should. But if we can reduce the dose intensity and treatment frequency and still have the same outcomes, then I guess in simple words, we're just trying to say use it when it's absolutely needed, or you can also look into other alternatives that might not need G-CSF but you could maintain the same outcomes. Brittany Harvey: Understood. It's helpful to review those options for clinicians and showing that there's not just one way to address potential neutropenic complications for later cycles of chemotherapy. So then following those recommendations for prophylaxis, what does the expert panel recommend regarding CSFs for the treatment of febrile neutropenia? Dr. Bishal Gyawali: This is an important question because this ties strongly with the "Choosing Wisely" campaign. In other words, primary and secondary prophylaxis we talked about when CSF should be used; here we make a sort of negative recommendation in that we say when CSF should not be used, because this is where we see most overuse or overtreatment with G-CSF. So first, we say that we should not be using a CSF routinely simply because a patient has neutropenia. If they are afebrile but they only have neutropenia, we recommend against using CSF just to boost neutrophil counts; that's not a meaningful metric. Then the second recommendation we make is CSF should not be routinely used as an adjunctive treatment with antibiotic therapy for patients with fever and neutropenia. So the first one was neutropenia, no fever, don't use it. The second one is okay, there is neutropenia and fever, but the treatment for that is use of antibiotic therapy, and so in such situations routinely we should not be using G-CSF just to boost the neutrophil count. And that is tied on to the third recommendation where if the patient has fever and neutropenia but is also at a very high risk for infection-related complications or who have other prognostic factors that we think will lead to poor outcomes for the patient, then in such situations, a CSF can be used as an adjunctive treatment. But we talk about the data in the manuscript, but the data show that the most that this will do is reduce the days of hospitalization by a couple of days. It actually does not have any data that it's going to improve the mortality rates. So as of now, we use the word "may be offered," it's not "should be offered," it's "may be offered" if there are other factors that we think will make the patient at the very poor risk of mortality outcomes, and the evidence quality here therefore is low and our strength of recommendation is conditional. And we also have a box that lists those items that we think might be associated with poor prognosis for the patients, but again the data for those, are they really hard evidence? No. And that is also tied with our future research recommendation that we should study more about these factors that might lead to these poor outcomes. Dr. Tessa Cigler: And again, allowing for discretion of the treating physician. Brittany Harvey: Absolutely. It's just as important to know when not to use CSFs routinely, and those risk factor boxes that you mentioned are available in the full manuscript along with the full list of recommendations, and our listeners can refer to that; a link will be in the show notes of the episode . Dr. Tessa Cigler: Just so you know, the panel, we really discussed those criteria a lot and agonized over them and gave you our best recommendations. Brittany Harvey: Definitely, and it sounds like there was varying degrees of evidence to support a lot of those risk factors, and so it's really important that the evidence supports those, but also there was expert consensus of the panel in reviewing each of those factors individually to come up with recommendations that can be applicable for all clinicians. Dr. Bishal Gyawali: If I may add, we're proud of our panel because I think our panel is quite inclusive of people representing different specialties within cancer care, as in we had radiation oncologist, we had infectious disease expert, pharmacists, and most importantly, we also had patient partners. Brittany Harvey: Absolutely. Having a multidisciplinary panel is really important for each and every guideline. So then, this is probably relevant now, but addressing a few more specific sections addressed in the guideline, what is the role of CSFs as adjuncts to progenitor cell transplantation? Dr. Tessa Sigler: Great question, and so, as solid tumor oncologists, Dr. Gyawali and I really leaned heavily on our hematology experts within the panel. The panel decided that a CSF should be used alone after chemotherapy or in combination with a CXCR4 inhibitor to mobilize peripheral blood progenitor cells. Clearly the choice of mobilization strategy depends on the type of cancer and the type of transplantation. The panel noted that a CSF should be routinely administered after autologous stem cell transplantation to reduce the risk of severe neutropenia, and that a CSF may be administered after allogeneic stem cell transplant to reduce the duration of severe neutropenia. Again, this last recommendation has not a lot of evidence to support it, and so we kind of tempered our language that it may be administered or can be considered based on clinical judgment of the physician and the clinical status of the patient. Brittany Harvey: And that really highlights the need for a multidisciplinary panel, because as you are solid tumor oncologists, you need the hematologists to make recommendations for all sorts of patients and make sure that these guidelines are comprehensive.   So then moving on to another smaller subset population, for patients receiving concomitant chemotherapy and radiation therapy, are CSFs recommended? Dr. Bishal Gyawali: I think there is very little evidence for patients who are receiving radiation therapy alone, so there is no evidence to suggest the use of CSF in patients with radiation therapy alone. The bigger question is in patients who are receiving both chemo and radiation together, chemoradiotherapy. In those patients, up until now, the classical recommendation has been to avoid G-CSF use. I think in our updated guidelines we discuss a couple newer trials that are trying to address this issue, but in the totality of evidence, we still stick with the same recommendation as before, which is CSFs are not recommended in patients receiving concomitant chemotherapy and radiation therapy, especially those involving the mediastinum because the biggest evidence of harm is for these patients. Dr. Tessa Cigler: I agree completely. Brittany Harvey: Definitely. It's important to recognize when that balance of benefits and harms leans more towards harms, and so that this should not be recommended for those patients. So there are several different CSFs that are recommended in the guideline, including biosimilars. So do the recommended CSFs differ in efficacy or safety? Dr. Tessa Cigler: So as supported by evidence, and the panel all agreed, that the various forms of CSFs, including the biosimilars, really have the same evidence for efficacy and for safety, and that the choice of agent really should depend on cost, availability, accessibility, patient convenience, and sometimes disease subtypes and treatment regimens. But, in essence, these can be used interchangeably without concern for efficacy or toxicity differences. Dr. Bishal Gyawali: I completely agree. I think in terms of efficacy outcomes, I don't think there is anything to choose between these agents. The choice between these agents would largely depend on different patient and treatment-related factors: cost, availability, affordability, feasibility. We even discuss things like where does the patient live, as in how frequently the patient can commit to the cancer center, and we also discussed things like even for the daily shots of filgrastim, patients can be taught and they can get it by themselves at home. So we discussed all these factors, but in a nutshell, the choice within these agents primarily depends not on efficacy factors, but simply based on all these other factors that are equally important but which can lead to informed decision-making about what is best for a given patient. But we mention it explicitly that the biosimilars, there is nothing to choose between them, especially the biosimilars; it's about price competition and what you can get at an affordable rate. Brittany Harvey: Understood. It's great to have many different options for patients so that there's something that can work for them based off access, cost, and all these factors that you listed. As you mentioned, it may be easier for some patients to get their treatment at home rather than in clinic, and so having different options and reviewing those with patients is very important. Dr. Bishal Gyawali: As we are having this conversation, I'm thinking that we might be a very unique guideline in that I don't think in many other settings you have this many options that you are asking about, you know, choices between equally good options and making decisions based on cost. I don't think there are any other areas in oncology where we have the privilege of making these decisions based on cost and convenience and all these factors, as well as we might be one of those guidelines where we have, as discussed before, so many recommendations about when not to do things and trying to promote judicial use of treatments. Dr. Tessa Cigler: As you might imagine, our panel discussions were very lively. Dr. Bishal Gyawali: Yes. But Dr. Cigler, do you recall any other guideline where there is so much discussion about when not to use things and how we have so many biosimilar options and we can choose the one that's most appropriate? I don't recall any other. Dr. Tessa Cigler: I agree with you. Brittany Harvey: It's certainly a unique guideline in that regard. So we'll move into the last clinical question that the expert panel addressed. But what does the expert panel recommend for the initiation, duration, dosing, and administration of CSFs? Dr. Bishal Gyawali: Yeah, I think there has been some new data in this regard that were not available in the previous guideline. For example, we have new trials testing a shorter duration of filgrastim injections compared to the standard of care. So we have some data, we call this 'de-escalation of treatment'. So we have more data supporting de-escalation of treatment. We have some data for lower dose of pegfilgrastim, we have data for lower duration of filgrastim, we have also some new data about timing of treatment, as in there has been some newer data presented about the relationship of timing of the drug and the frequency of adverse events from G-CSF such as bone pain. There is also the question about, for patients who don't live near the cancer center, can they get their pegfilgrastim shot on the day of chemo while they are in the cancer center? So all these questions that are very pragmatic and important questions, but were not answered before, we're glad that we had more evidence to talk about all these factors and give a more solid recommendation to our users of the guideline. Brittany Harvey: Definitely. And listeners can review the full list of dosing and administration recommendations in Table 2 in the guideline, and that will be linked in the show notes of the episode. So then I really want to thank you both for reviewing all of these recommendations. There's certainly a large amount of clinical questions and recommendations that you went through. I'd like to next ask, in your view, what is the importance of this updated guideline and how will it impact both clinicians and patients? Dr. Bishal Gyawali: I think the importance of this updated guideline is that, as mentioned before, we talk about newer data that have come up with regards to not just the most important two questions as in when to use it as primary prophylaxis and when to use it as secondary prophylaxis and when to use it as treatment, but also with regards to the duration and timing and dosing and multiple options and how these all factors as well as patient-related factors should be combined to make an informed decision, the most appropriate decision for the patient. And as mentioned before, we have the GRADE tables that were not in the previous version of this guideline. So I think even those users that are familiar with the 2015 guideline, I think they will find very novel content in this new updated guideline, and they will find it useful for their practice. I would encourage the readers to not only read the headlines of the box recommendations, but also read the full text of these guidelines because we have worked really hard to incorporate the latest evidence and also interpret them contextually. The discussion regarding de-escalation, patient considerations, cost implications; usually, people just skip these portions when they read a guideline. But I think these are also one of the most important paragraphs in our guideline, so they have been written with very careful thought, and I think reading the whole guideline is very much worth your time. Dr. Tessa Cigler: As you can imagine, I agree completely, having just spent several months thinking about these guidelines and all their nuances. Brittany Harvey: Certainly, this guideline is definitely a very comprehensive update, and that nuance in the manuscript is really important for clinicians to understand and read through and understand when it's appropriate to make certain decisions. So then to wrap us up, I'd like to ask, what are the outstanding questions and active research areas regarding the use of white blood cell growth factors in patients with cancer? Dr. Tessa Cigler: As you all know from clinical practice and that we've said several times already in this podcast is that the risk factors for the development of complications of febrile neutropenia are still not clearly worked out. And one of the things that is, I think, really needed in clinical practice is the development of predictive algorithms or biomarkers to really allow us to understand who might be more at risk and to allow for the clinician to be able to tailor the use of G-CSF as needed. Brittany Harvey: Yes, and so we'll look forward to future updates in this space to inform new recommendations and an updated guideline in the future. So I want to thank you both so much for your work to develop this comprehensive guideline. It was certainly a lot of effort, and thank you for your time today, Dr. Gyawali and Dr. Cigler. Dr. Tessa Cigler: Oh, my pleasure. It's nice to be here and to speak with you all. Dr. Bishal Gyawali: Yeah, it was great to speak with both of you but also through you to the audience, and we had a great time. Thank you. Brittany Harvey: And then finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Are you "Grade A Supply" without even knowing it?Most people think narcissists target "broken" people. As a self-aware narcissist, I'm telling you that's a lie. We want the best. We want the person with the biggest heart, the most success, and the most to give. But there is a dark side to being "the best"—to a narcissist, you are a high-value asset that is ultimately replaceable.IN THIS LIVE, WE ARE DISCUSSING:The Anatomy of Grade A Supply: The 4 traits that make you an irresistible target.The "Reflector" Effect: How we use your light to hide our darkness.The Cold Truth on Replaceability: Why we can move on in 24 hours even after you gave us everything.Breaking the Pedestal: How to stop being "supply" and start being a person again.If you've ever felt like you were "special" to them only to be discarded like trash, this Live is for you.Connect with Lee:My Courses: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://courses.mentalhealness.net⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 1-on-1 Coaching Calls: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://link.me/mentalhealness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠All My Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://beacons.page/mentalhealness ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow on Instagram/TikTok: @mentalhealnesssIf this episode helped you gain clarity, please leave a 5-star review on Spotify! It helps others find the validation they need to heal.

The boys in Orange and Blue are back and so are Adam and Adam to recap Matchday 1.Cincy grabs a 2-0 victory over Atlanta to start the campaign and there are no shortages of storylines and performances to to talk about.There were several candidates for Man of the Match and Adam perhaps picked a controversial one, but the stats back it.Listen up!!!!@TheKingAdRock73 @NinoOne @sbucks67 @crackityFC @ComeOnYouFCC @fccincinnati @Zuhause513 @MLS #AllForCincy #FCCincy #YAL #WestEndBoys

In this third collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma (Philadelphia, USA) and Benedikt Huttner (WHO, Geneva, Switzerland) [1-3]. Together, they deconstruct the complex landscape of developing and implementing guidelines into digestible components: they discuss why different organizations develop guidelines and what need they hope to fulfil, the framework including the GRADE methodology under which guidelines are written, and major barriers in the uptake of guidelines. The conversation also details the distinction between guideline and guidance as well as the art and science behind formulating recommendations or suggestions, with a few anecdotal cases sprinkled in from the panel. References 1. WHO handbook for guideline development, 2nd Edition, https://www.who.int/publications/i/item/9789241548960 2. The WHO AWaRe (Access, Watch, Reserve) antibiotic book https://www.who.int/publications/i/item/9789240062382 3. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections, https://www.idsociety.org/practice-guideline/amr-guidance/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

The Iowa State season cancellation mystery finally has an answer—at least from the administration. We dive into the internal conflicts, the AD's letter to families, and why the "safety" claims don't add up. Plus, we compare the Winter Olympics to gymnastics: what should we steal from Figure Skating's judging and NCAA updates HEADLINES Major Update on the Iowa State Season cancellation. Read the letter here Ana Barbosu whereabouts investigation Elite Season Begins! CHAPTERS 0:00 Intro: The 2026 Elite Season Begins 1:14 The Bileses: Jonathan Owens Theft Attempt in Milan 3:53 Iowa State Scandal: Why the Season Was Really Cancelled 10:43 Breaking: Ana Barbosu Under Investigation (Whereabouts Violations) 14:25 2026 Elite Kickoff: Winter Cup & Cottbus World Cup Preview 18:35 Winter Olympics: A Gymnast's Perspective 21:01 What Gymnastics Must Learn From Figure Skating 35:42 The Case for a "Grade of Execution" (GOE) Judging System 50:15 Why Gymnastics Needs Live Technical Scoring Boxes 1:05:10 Commentary & Artistry: We Need "Johnny Weir Energy" 1:14:25 Olympic Traditions: Throwing Stuffed Animals & Logistics 1:25:40 NCAA Update: The Race for Perfect 10s & Regional Rankings 1:38:15 Comedy Award of the Week: The Beam Save 1:41:34 Join Us for College & Cocktails: LSU vs. Oklahoma UP NEXT Fantasy Gymnastics podcast every Wednesday College & Cocktails: Friday,  7:30 pm Pacific where we will watch LSU at Oklahoma on ESPN2 2026 Cocktail and Mocktail menu here Add exclusive Club Content to your favorite podcast player (instructions here). UPDATES Attention! We are giving away 2 tickets to the American Cup in Las Vegas  Check us out on Bluesky NEW Team Bronze Design in the store! Join our Live Shows Replay tickets on sale for our fundraiser show with all the Tea from Cecile Landi 2026 Live Show Season Pass is now available, 4 shows for the price of 3 SUPPORT OUR WORK Club Gym Nerd: Join Here Fantasy: 2026 College Fantasy Game now open all season with weekly winners Merch: Shop Now Newsletters The Balance Beam Situation: Spencer's GIF Code of Points Gymnastics History and Code of Points Archive from Uncle Tim Resistance Resources Thanks to our Sponsor:  Limited Time Offer – Get Huel today with my exclusive offer of 15% OFF online with my code [GymCastic15] at huel.com/[GymCastic15]. New Customers Only. Thank you to Huel for partnering and supporting our show!